Immune Checkpoint Inhibitors May Increase Risk of Serious Infection

Nearly a quarter of patients receiving a variety of drugs classified as immune checkpoint inhibitors develop infections during treatment and 15% are considered severe, researchers reported in study findings published in Cancer Medicine.